建立新的患者来源异种移植人源化小鼠模型以研究人特异性肿瘤微环境与免疫治疗
为研究人肝细胞癌(HCC)与免疫系统相互作用及人特异性药物测试,研究者将患者来源异种移植瘤与I类人类白细胞抗原匹配的人免疫系统共同植入NOD-scid Il2rg-/-(NSG)小鼠,建立人源化小鼠模型。该模型中人免疫系统被肿瘤教育并呈现耗竭表型,肿瘤浸润T细胞耗竭标志物表达更高、细胞因子产生更低,肿瘤相关巨噬细胞与髓系来源抑制细胞高度富集,且肿瘤通过上调免疫检查点配体改变基因表达谱。与NSG模型不同,该模型同时再现帕博利珠单抗和伊匹木单抗的治疗效应与副作用。
要点
- 患者来源异种移植瘤与HLA-I匹配人免疫系统在NSG小鼠中建立人源化模型。
- 模型中人免疫系统被肿瘤教育,呈现耗竭表型,细胞毒性免疫细胞减少更快。
- 肿瘤浸润T细胞耗竭标志物表达更高、细胞因子产生更低,肿瘤微环境中巨噬细胞与髓系来源抑制细胞富集。
核心结论
- 该工作为免疫肿瘤学研究提供了模型,并为抗HCC药物测试特别是免疫治疗提供了有用的平行于人的平台。
研究设计与样本
- 患者来源异种移植瘤与I类人类白细胞抗原匹配的人免疫系统在NOD-scid Il2rg-/-(NSG)小鼠中建立。
- 纵向研究肿瘤与免疫反应变化以及免疫检查点抑制剂的疗效。
主要发现
- 与临床结局相似,模型中人免疫系统被肿瘤教育并呈现耗竭表型,包括白细胞数量显著下降、耗竭标志物上调及人促炎细胞因子产生减少。
- 细胞毒性免疫细胞较其他细胞类型下降更快。
- 肿瘤浸润T细胞较外周T细胞耗竭标志物表达更高且细胞因子产生更低。
- 肿瘤相关巨噬细胞与髓系来源抑制细胞在肿瘤微环境中高度富集。
- 肿瘤通过上调免疫检查点配体改变基因表达谱以响应免疫反应。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: As the current therapeutic strategies for human hepatocellular carcinoma (HCC) have been proven to have limited effectiveness, immunotherapy becomes a compelling way to tackle the disease. We aim to provide humanised mouse (humice) models for the understanding of the interaction between human cancer and immune system, particularly for human-specific drug testing. DESIGN: Patient-derived xenograft tumours are established with type I human leucocyte antigen matched human immune system in NOD-scid Il2rg-/- (NSG) mice. The longitudinal changes of the tumour and immune responses as well as the efficacy of immune checkpoint inhibitors are investigated. RESULTS: Similar to the clinical outcomes, the human immune system in our model is educated by the tumour and exhibits exhaustion phenotypes such as a significant declination of leucocyte numbers, upregulation of exhaustion markers and decreased the production of human proinflammatory cytokines. Notably, cytotoxic immune cells decreased more rapidly compared with other cell types. Tumour infiltrated T cells have much higher expression of exhaustion markers and lower cytokine production compared with peripheral T cells. In addition, tumour-associated macrophages and myeloid-derived suppressor cells are found to be highly enriched in the tumour microenvironment. Interestingly, the tumour also changes gene expression profiles in response to immune responses by upregulating immune checkpoint ligands. Most importantly, in contrast to the NSG model, our model demonstrates both therapeutic and side effects of immune checkpoint inhibitors pembrolizumab and ipilimumab. CONCLUSIONS: Our work provides a model for immune-oncology study and a useful parallel-to-human platform for anti-HCC drug testing, especially immunotherapy.
引用
- Zhao Y, Shuen TWH, Toh TB, et al. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy. Gut. 2018. PMID: 29602780. doi:10.1136/gutjnl-2017-315201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。